title: News products to avoid.
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D000077784:Axitinib; D001374:Azacitidine / Q000009:adverse effects / Q000031:analogs & derivatives; D000077209:Decitabine; D004338:Drug Combinations; D064420:Drug-Related Side Effects and Adverse Reactions / Q000175:diagnosis / Q000209:etiology*; D000068338:Everolimus; D052203:Ferrosoferric Oxide / Q000009:adverse effects; D000077156:Gefitinib; D006397:Hematinics / Q000009:adverse effects*; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects; D007191:Indazoles / Q000009:adverse effects; D010094:Oxonic Acid / Q000009:adverse effects; D011725:Pyridines / Q000009:adverse effects; D011799:Quinazolines / Q000009:adverse effects; D018570:Risk Assessment; D012307:Risk Factors; D020123:Sirolimus / Q000009:adverse effects / Q000031:analogs & derivatives; D005641:Tegafur / Q000009:adverse effects
chemical_list: D000970:Antineoplastic Agents; D004338:Drug Combinations; D006397:Hematinics; D007093:Imidazoles; D007191:Indazoles; D011725:Pyridines; D011799:Quinazolines; C586502:tegafur-gimeracil-oteracil; D005641:Tegafur; D010094:Oxonic Acid; D000077209:Decitabine; D000068338:Everolimus; D000077784:Axitinib; D001374:Azacitidine; D000077156:Gefitinib; D020123:Sirolimus; D052203:Ferrosoferric Oxide